Galapagos NV (GLPG)

Currency in EUR
28.18
-0.02(-0.07%)
Real-time Data·
GLPG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.1028.74
52 wk Range
20.0032.74
Key Statistics
Prev. Close
28.2
Open
28.5
Day's Range
28.1-28.74
52 wk Range
20-32.74
Volume
23.72K
Average Volume (3m)
90.58K
1-Year Change
23.38%
Book Value / Share
37.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLPG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.58
Upside
+4.96%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Galapagos NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Compare GLPG to Peers and Sector

Metrics to compare
GLPG
Peers
Sector
Relationship
P/E Ratio
−4.2x16.8x−0.6x
PEG Ratio
0.010.090.00
Price/Book
0.8x4.8x2.6x
Price / LTM Sales
6.5x4.9x3.4x
Upside (Analyst Target)
−0.9%45.1%42.0%
Fair Value Upside
Unlock5.7%5.8%Unlock

Analyst Ratings

1 Buy
5 Hold
4 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 29.58
(+4.96% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Sell22.00-21.93%-Maintain07/01/2026
Bernstein SocGen Group
Hold27.90-0.99%-New Coverage25/11/2025
Deutsche Bank
Sell19.00-32.58%22.00Downgrade05/08/2025
Deutsche Bank
Hold22.00-21.93%-Maintain28/04/2025
Deutsche Bank
Hold22.00-21.93%28.00Maintain19/02/2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-3.07 / -0.30
Revenue / Forecast
71.13M / 67.96M
EPS Revisions
Last 90 days

People Also Watch

24.96
SOLB
+0.65%
113.95
KBC
-1.56%
19.32
UMI
+1.74%
11.51
VLOF
+0.88%
21.7700
FBK
-2.16%

FAQ

What Is the Galapagos (GLPG) Share Price Today?

The live Galapagos share price today is 28.18

What Stock Exchange Does Galapagos (GLPG) Trade On?

Galapagos is listed and trades on the Amsterdam Stock Exchange.

What Is the Ticker (Stock Symbol) for Galapagos?

The stock symbol (also called a 'ticker') for Galapagos is "GLPG."

What Is the Current Galapagos Market Cap?

As of today, Galapagos market capitalisation is 1.85B.

What Is Galapagos's (GLPG) Earnings Per Share (TTM)?

The Galapagos EPS is currently -6.74 (Trailing Twelve Months).

When Is the Next Galapagos Earnings Date?

Galapagos's next earnings report will be released on 24 Feb 2026.

Is GLPG a Buy or Sell From a Technical Analyst Perspective?

Based on today's Galapagos moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Galapagos Stock Split?

Galapagos has split 0 times. (See the GLPG stock split history page for full effective split date and price information.)

How Many Employees Does Galapagos Have?

Galapagos has 704 employees.

What is the current trading status of Galapagos (GLPG)?

As of 21 Jan 2026, Galapagos (GLPG) is trading at a price of 28.18, with a previous close of 28.20. The stock has fluctuated within a day range of 28.10 to 28.74, while its 52-week range spans from 20.00 to 32.74.

What Is Galapagos (GLPG) Price Target According to Analysts?

The average 12-month price target for Galapagos is EUR29.58, with a high estimate of EUR44.8 and a low estimate of EUR19. 1 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +4.96% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.